ALTDORF, Switzerland—Datwyler Group recently announced that it is strengthening its position in the U.S. by investing more than $102 million in a new plant in Delaware. The new plant will be used to manufacture high-quality elastomer components for injectable drug delivery systems. According to a release from Datwyler, the highly automated facility meets the most stringent quality standards.
Datwyler is further expanding its production capacity for high-quality elastomer components for injectable drug delivery systems. Production is scheduled to start in the first half of 2018. Once it is fully up and running, Datwyler’s new, highly automated plant in the U.S. is expected to provide jobs for about 120 employees.
Datwyler, which has been operating its own plant in the U.S. since 1981, is a supplier to prominent health care and pharmaceutical providers in America. With its new production site in Delaware, the company will be able to significantly boost its position in the world’s largest pharmaceutical market.
The new plant is to be designed, built, and run in accordance with Datwyler’s latest “FirstLine” standards. This will make it possible to provide customer in three key business regions— the U.S., Europe, and Asia—with locally produced first-line components. The FirstLine standards comprise a manufacturing concept for high-quality elastomer components based on what the company calls “ultra-modern clean room technology, automated production cells, fully automated camera inspection, and a unique washing process.” This approach to manufacturing is reported to exceed the most stringent quality standards of the European and U.S. regulatory authorities, and is certified to ISO 15378.